AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
Log in

NASDAQ:LOGCLogicBio Therapeutics Earnings Date, Estimates & History

$8.54
-0.22 (-2.51 %)
(As of 07/2/2020 03:25 PM ET)
Add
Compare
Today's Range
$8.54
Now: $8.55
$8.99
50-Day Range
$6.07
MA: $7.28
$8.41
52-Week Range
$3.05
Now: $8.55
$14.00
Volume18,856 shs
Average Volume69,449 shs
Market Capitalization$200.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65

Earnings

LogicBio Therapeutics (NASDAQ:LOGC) Earnings Information

LogicBio Therapeutics last announced its earnings data on May 11th, 2020. The reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.07. The business earned $1.02 million during the quarter. LogicBio Therapeutics has generated ($1.78) earnings per share over the last year. LogicBio Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 11th, 2020 based off prior year's report dates.

LogicBio Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LogicBio Therapeutics (NASDAQ:LOGC) Earnings Estimates

2020 EPS Consensus Estimate: ($2.08)
2021 EPS Consensus Estimate: ($2.84)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20201($0.51)($0.51)($0.51)
Q2 20202($0.64)($0.42)($0.53)
Q3 20202($0.58)($0.46)($0.52)
Q4 20202($0.57)($0.47)($0.52)
Q1 20211($0.52)($0.52)($0.52)
Q2 20211($0.73)($0.73)($0.73)
Q3 20211($0.78)($0.78)($0.78)
Q4 20211($0.81)($0.81)($0.81)

LogicBio Therapeutics (NASDAQ LOGC) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/11/2020
(Estimated)
       
5/11/20203/31/2020($0.48)($0.41)($0.41)$1.02 millionN/A
3/16/202012/31/2019($0.49)($0.51)($0.50)N/A
11/12/2019Q3($0.4630)($0.48)($0.48)N/A
8/13/2019Q2 2019($0.4070)($0.4470)($0.45)N/A
5/14/20193/31/2019($0.32)($0.34)($0.34)N/A
4/1/201912/31/2018($0.39)($0.41)($0.41)N/A
12/3/2018Q3($0.34)($4.03)($4.03)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.